Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Warfarin is FDA-approved for the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism), stroke prevention in atrial fibrillation, and thromboembolism prevention in patients with mechanical prosthetic heart valves. It is also used after certain cardiac events to reduce the risk of further clots and strokes.

Warfarin remains the anticoagulant of choice for patients with mechanical heart valves, as DOACs have not demonstrated adequate safety and efficacy in this high-risk population. For other indications (atrial fibrillation, VTE), DOACs have largely supplanted warfarin in patients who are eligible.

How It Works

Warfarin inhibits the enzyme vitamin K epoxide reductase (VKORC1), blocking the recycling of vitamin K into its active form. Vitamin K is essential for the hepatic synthesis of several coagulation factors: factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S. By depleting functional vitamin K, warfarin prevents the activation of these clotting factors, slowing the formation of blood clots.

Because warfarin targets clotting factor production rather than existing circulating factors, its anticoagulant effect is delayed — full therapeutic effect requires 5–7 days as existing functional clotting factors are gradually cleared from the circulation. This is why rapid anticoagulation (such as for acute DVT or PE) requires initial bridging with a rapid-acting parenteral anticoagulant (heparin or LMWH) until warfarin reaches therapeutic levels.

Warfarin's effect is quantified by the International Normalized Ratio (INR), a standardized measure of clotting time. Most indications require an INR of 2.0–3.0; mechanical heart valves may require a higher target range.

Side Effects

Common

• Bleeding — the primary risk of all anticoagulants; can range from minor (bruising, prolonged bleeding from cuts) to life-threatening
• Easy bruising
• Prolonged bleeding from minor cuts or dental procedures
• Nausea (uncommon)

Serious

• Major hemorrhage — intracranial, GI, urinary tract, or other serious sites; risk increases with supratherapeutic INR
• Warfarin-induced skin necrosis — rare; typically occurs early in therapy in patients with protein C or S deficiency, causing tissue death
• Purple toe syndrome — rare; cholesterol microemboli causing painful purple discoloration of toes
• Calciphylaxis — rare but serious complication in patients with renal disease
• Teratogenicity — warfarin embryopathy (nasal hypoplasia, stippled epiphyses, CNS abnormalities) with first-trimester exposure

Drug Interactions

Warfarin has more clinically significant drug and food interactions than virtually any other commonly prescribed medication. The following represents a selection of the most important interactions.

Drug / Class	Effect on INR	Clinical Significance
Antibiotics (metronidazole, fluconazole, ciprofloxacin, many others)	Increase INR (bleeding risk) — gut flora changes reduce vitamin K production; CYP inhibition	High — monitor INR closely after starting or stopping
Amiodarone	Markedly increases INR — CYP2C9 inhibition greatly elevates warfarin levels	Very High — dose reduction and close INR monitoring required
NSAIDs / Aspirin	No direct INR change, but dramatically increases bleeding risk through platelet inhibition and GI mucosal injury	High — avoid chronic NSAID use; use with aspirin only if specifically indicated
Rifampin	Markedly decreases INR — potent CYP induction accelerates warfarin metabolism	Very High — substantial dose increases required; monitor closely
Vitamin K-rich foods (leafy greens: kale, spinach, broccoli)	Decreases INR — competes with warfarin's mechanism	High — maintain consistent dietary vitamin K intake; dramatic changes in diet require INR monitoring
SSRIs / SNRIs	Mild INR increase through platelet inhibition and possible CYP2C9 inhibition	Moderate — monitor INR when starting or stopping
Herbal supplements (St. John's Wort, ginkgo, garlic)	Variable — St. John's Wort decreases INR; others may increase bleeding risk	Moderate–High — patients should disclose all supplements to prescriber

Warnings & Contraindications

Contraindications: Active pathological bleeding (e.g., hemorrhagic stroke, active GI bleed). Pregnancy (especially first trimester and near term) — Category X; causes fetal warfarin syndrome and increases fetal hemorrhage risk. Recent or planned surgery involving the brain, eye, or spinal cord where bleeding would be catastrophic. Unsupervised patients with high risk of non-compliance.

INR monitoring: Warfarin's therapeutic window is narrow. INR must be checked regularly — often weekly or biweekly when starting or adjusting therapy, and at least monthly when stable. INR outside the therapeutic range — either too low (clot risk) or too high (bleeding risk) — is common and requires dose adjustment.

Reversal: Warfarin anticoagulation can be reversed with vitamin K (phytonadione) or, in emergencies, with four-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP). This reversibility is a clinical advantage over some DOACs in certain settings.

Genetic factors: Variants in the CYP2C9 and VKORC1 genes significantly affect warfarin sensitivity. FDA-approved pharmacogenomics-guided dosing algorithms are available and may reduce the time to stable anticoagulation.

Frequently Asked Questions

Why do I need to limit vitamin K foods while on warfarin?

Warfarin works by blocking vitamin K's role in producing clotting factors. Eating large or inconsistent amounts of vitamin K-rich foods (kale, spinach, broccoli, Brussels sprouts) directly competes with warfarin's action and lowers the INR. The key is consistency, not elimination — patients can eat leafy greens regularly as long as intake is kept relatively stable from week to week and INR is monitored accordingly.

What is the INR and why does it matter?

The INR (International Normalized Ratio) measures how long it takes blood to clot relative to a standard. A normal INR is approximately 1.0. For most conditions treated with warfarin (atrial fibrillation, DVT/PE), the target INR is 2.0–3.0 — meaning blood clots two to three times more slowly than normal. An INR below target increases clot risk; above target increases bleeding risk.

Can I take ibuprofen or aspirin while on warfarin?

Ibuprofen and other NSAIDs are generally discouraged in patients on warfarin because they inhibit platelet function, damage the stomach lining, and can increase bleeding risk significantly — even without raising the INR. Aspirin may be used concurrently when specifically indicated (for example, in some mechanical valve patients), but only under medical supervision. Acetaminophen (Tylenol) is the preferred over-the-counter pain reliever for most warfarin patients, though high doses can also modestly raise the INR.

Are DOACs better than warfarin?

For most patients with atrial fibrillation or VTE, DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) offer comparable or superior efficacy with a lower risk of intracranial hemorrhage and require no INR monitoring. However, warfarin remains the preferred agent for mechanical heart valves, and may be preferred in patients with severe renal impairment, cost constraints, or who need a reliably reversible anticoagulant with an established antidote.

→ Blood Thinner Side Effects Guide